Prostatectomy News and Research

RSS

SiMoA technology measures individual PSA molecules in prostate cancer patients: Nature Biotechnology

Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company's proprietary technology that demonstrates an unprecedented sensitivity for measuring a biomarker for prostate cancer recurrence.

24 May 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

Preoperative MRI helps spare erectile function, continence after RALP for prostate cancer

Preoperative prostate magnetic resonance imaging (MRI) can help urologic surgeons spare the neurovascular bundle (NVB) (which controls a man's erectile function and continence) during a robotic assisted laparoscopic prostatectomy (RALP) for the treatment of prostate cancer, according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

7 May 2010

Myriad Genetics' third-quarter fiscal 2010 revenues increase 5% to $90.8M

Myriad Genetics, Inc. today reported financial results for the third fiscal quarter and the nine-month period ended March 31, 2010.

5 May 2010

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.

29 Apr 2010

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Interest in cancer prevention is increasing as scientists continue to learn new information and confirm what was already suspected.

22 Apr 2010

PTEN expression clinically useful in assessing risk of prostate cancer recurrence: Study

Myriad Genetics, Inc. today said results from a recent study indicate that expression of the PTEN gene may be clinically useful in assessing a man's risk of prostate cancer recurrence after radical prostatectomy.

20 Apr 2010

Updated clinical guidelines presented at EAU Anniversary Congress

A number of updated guidelines are presented at the Anniversary Congress of the European Association of Urology (EAU) held in Barcelona, from 16 through 20 April. The abridged versions - Pocket Guidelines - which are based on the extended text documents will also be available in Barcelona to all EAU members and press.

17 Apr 2010

Prostate cancer patients having robotic prostatectomy enjoy significant benefits: Study

A new study of almost 700 patients from The Mount Sinai Medical Center shows that prostate cancer patients who had robotically assisted prostatectomy enjoyed significant benefits over patients who had a traditional open radical prostatectomy, including decreased surgical and recovery time, less blood loss during surgery and significantly shorter hospital stays.

16 Apr 2010

Trans-urethral prostate hyperthermia treatment offers 100% response rate

According the Dr. Friedrich Douwes, Medical Director of St. George Hospital in Bad Aibling, Germany, president of the German Oncological Society and the author of several hundred scientific articles and books, trans-urethral prostate hyperthermia has a 100% initial response rate.

16 Apr 2010

MR-guided ablation therapy may hold promise for treatment of prostate cancer recurrences

The first known patient cases using magnetic resonance-guided heat (laser interstitial thermal therapy) or cold (cryoablation) to treat prostate cancer recurrence after surgical removal of the prostate gland were presented by physicians at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa. Many of these patients have also failed salvage radiation treatment and are often presented with limited therapeutic options. MR-guided focal therapy offers a new treatment choice for patients because of the improved detection of early prostate cancer recurrences best seen with MR imaging.

18 Mar 2010

Study supports Myriad Genetics' PROLARIS molecular diagnostic test for predicting prostate cancer recurrence

Myriad Genetics, Inc. today said data that provides further clinical validation supporting its newest molecular diagnostic product, PROLARIS™, was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco. The abstract of the presentation entitled: "Cell Cycle Genes Predict Recurrence After Radical Prostatectomy" by Gregory P. Swanson, M.D., University of Texas Health Science Center San Antonio, and colleagues is now available on the American Society of Clinical Oncology's website, www.asco.org.

11 Mar 2010

Two core premises underlie MSI's mission to broaden access to surgical choice and quality

Two core premises underlie Mobile Surgery International's mission to broaden access to surgical choice and quality. The first is that patients (and payers) should be able to make decisions about surgical options based upon access to complete information up front about all of the necessary services associated with their surgical procedure, the skill and expertise of the surgeon carrying out the procedure, and the total costs involved.

10 Mar 2010

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

New research published in today's issue of the Archives of Internal Medicine (Vol. 170, No. 5), by an investigator at The Cancer Institute of New Jersey and colleagues at Memorial Sloan-Kettering Cancer Center in New York, shows that the type of specialist that men with localized prostate cancer see can influence the form of therapy they ultimately receive.

9 Mar 2010

Prostate cancer: Therapy depends on consulted specialty

Men who visit a radiation oncologist appear more likely to receive radiation therapy for prostate cancer, whereas men who consult with a urologist with or without a medical oncologist are treated more frequently with hormone therapy, watchful waiting or a radical prostatectomy, according to a report in the March 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

9 Mar 2010

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Robotic surgical technology with its three-dimensional, high-definition view gives surgeons the sensation of touch, even as they operate from a remote console. A new study describes the phenomenon, called intersensory integration, and reports that surgical outcomes for prostate cancer surgery using minimally invasive robotic technology compare favorably with traditional invasive surgery.

3 Mar 2010

HealthGrades America’s 50 Best Hospitals for 2010 identified

The HealthGrades America’s 50 Best Hospitals for 2010 were identified in a report issued today by the leading independent healthcare ratings organization. The analysis, which examined objective patient outcomes over three years at all 5,000 of the nation’s nonfederal hospitals, found that the 50 Best Hospitals had mortality rates that were, on average, 27% lower than other hospitals.

25 Feb 2010

Study comparing open and laparoscopic radical prostatectomy reveals few differences in outcomes

Of the 200,000 men newly diagnosed with prostate cancer each year in the United States, about one-third will undergo surgical treatment. Although open radical prostatectomy (ORP) is regarded as the standard treatment, laparoscopic radical prostatectomy (LRP) with or without robotic assistance is becoming more common.

22 Feb 2010

Olympus launches new medical devices for LESS surgery

A variety of new medical devices specifically designed for Laparo-Endoscopic Single-Site surgery (LESS surgery) has been announced and introduced by Olympus Europa Holding GmbH and Olympus Medical Systems Corporation. LESS surgery is an advanced, minimally invasive operation technique by which an endoscope and hand instruments are inserted through an access port anchored in just one small incision, usually made in the navel. After developing all the medical devices needed to perform LESS surgery, Olympus has yet again proven its leadership in the field. The release of these innovative devices in Europe took place in autumn 2009.

From Evident Corporation - Life Sciences 18 Feb 2010

U.S. PSA screening efficacy lower than in ERSPC-Rotterdam due to lower testing sensitivity

Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the U.S. than in a European randomized trial because of lower screening sensitivity, according to a new brief communication published online February 8 in the Journal of the National Cancer Institute.

9 Feb 2010